发布求助
文献互助 智能选刊 最新文献

Pharmadeals Review最新文献

筛选
英文 中文
Roche to Buy InterMune for US$8.3 B to Gain Pirfenidone for Idiopathic Pulmonary Fibrosis 罗氏83亿美元收购InterMune获得特发性肺纤维化药物吡非尼酮
Pharmadeals Review Pub Date : 2014-09-24 DOI: 10.3833/PDR.V2014I9.2063
Heather Cartwright
{"title":"Roche to Buy InterMune for US$8.3 B to Gain Pirfenidone for Idiopathic Pulmonary Fibrosis","authors":"Heather Cartwright","doi":"10.3833/PDR.V2014I9.2063","DOIUrl":"https://doi.org/10.3833/PDR.V2014I9.2063","url":null,"abstract":"In its fifth M&A deal of 2014 so far, Roche has agreed to buy its former partner InterMune for approximately US$8.3 B in an all-cash deal, the company’s largest since its US$46.8 B purchase of 44% of Genentech in 2009. With the acquisition, Roche will gain InterMune’s idiopathic pulmonary fibrosis drug pirfenidone, which is approved in Europe and Canada as Esbriet® and which is awaiting a regulatory decision in the US. The deal will expand Roche’s small respiratory franchise, which include Pulmozyme® (dornase alpha) for cystic fibrosis and Xolair® (omalizumab) for allergic asthma.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"15 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2014-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84393468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pfizer Pays Merck KGaA US$850 M Upfront to Compete in Immuno-Oncology 辉瑞向默克支付8.5亿美元，在免疫肿瘤学领域展开竞争
Pharmadeals Review Pub Date : 2014-09-12 DOI: 10.3833/PDR.V2014I12.2082
Heather Cartwright
{"title":"Pfizer Pays Merck KGaA US$850 M Upfront to Compete in Immuno-Oncology","authors":"Heather Cartwright","doi":"10.3833/PDR.V2014I12.2082","DOIUrl":"https://doi.org/10.3833/PDR.V2014I12.2082","url":null,"abstract":"In a deal that suggests that it may no longer be interested in acquiring AstraZeneca, Pfizer has agreed to pay Merck KGaA US$850 M upfront in order to co-develop and co-commercialise the German company’s anti-PD-L1 (programmed deathligand-1) antibody MSB0010718C, which is being evaluated in a Phase II trial in patients with Merkel cell carcinoma. The deal, which provides a much-needed boost to Merck’s pipeline prospects, will help advance Pfizer’s position in the highly competitive immuno-oncology field. It also allows Merck to enter the US oncology market by giving it co-promotion rights to Pfizer’s Xalkori® (crizotinib).","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"73 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2014-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84380965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Salix Joins the Tax Inversion Wave by Agreeing to Merge with Cosmo Pharmaceuticals’ Irish Unit Salix加入税收倒置浪潮，同意与Cosmo制药公司的爱尔兰子公司合并
Pharmadeals Review Pub Date : 2014-08-27 DOI: 10.3833/pdr.v2014i8.2054
Heather Cartwright
{"title":"Salix Joins the Tax Inversion Wave by Agreeing to Merge with Cosmo Pharmaceuticals’ Irish Unit","authors":"Heather Cartwright","doi":"10.3833/pdr.v2014i8.2054","DOIUrl":"https://doi.org/10.3833/pdr.v2014i8.2054","url":null,"abstract":"Continuing the tax inversion trend among US-based companies in the life sciences sector, Salix Pharmaceuticals has agreed to buy the Ireland-domiciled subsidiary of Italian speciality pharmaceutical company Cosmo Pharmaceuticals in an all-stock deal valued at approximately US$2.7 B. The deal will lower Salix’s effective long-term tax rate from the high 30% range at present to the low 20% range and will give the company ownership of Cosmo’s US patents for three gastrointestinal products, including Uceris® (budesonide) for ulcerative colitis.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"25 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2014-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73839967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lundbeck Adds to Neurology Portfolio with Chelsea Therapeutics Acquisition Lundbeck收购Chelsea Therapeutics，增加神经学投资组合
Pharmadeals Review Pub Date : 2014-06-06 DOI: 10.3833/PDR.V2014I6.2039
Heather Cartwright
{"title":"Lundbeck Adds to Neurology Portfolio with Chelsea Therapeutics Acquisition","authors":"Heather Cartwright","doi":"10.3833/PDR.V2014I6.2039","DOIUrl":"https://doi.org/10.3833/PDR.V2014I6.2039","url":null,"abstract":"H. Lundbeck has agreed to buy Chelsea Therapeutics for US$530 M upfront in order to add the orphan drug Northera™ (droxidopa) to its US neurology portfolio. After previously being rejected by the US FDA, Northera was granted accelerated approval in February 2014 for the treatment of symptomatic neurogenic orthostatic hypotension. Chelsea shareholders will also receive contingent value rights that could pay up to US$1.50 per share dependent on sales levels of Northera in the period 2015-2017, bringing the potential total deal value to US$658 M.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"155 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2014-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86299490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
BioAlliance Pharma and Topotarget Agree to Merge and Combine Late-State Orphan Oncology Assets BioAlliance Pharma和Topotarget同意合并晚期孤儿肿瘤资产
Pharmadeals Review Pub Date : 2014-05-16 DOI: 10.3833/PDR.V2014I5.2027
Heather Cartwright
{"title":"BioAlliance Pharma and Topotarget Agree to Merge and Combine Late-State Orphan Oncology Assets","authors":"Heather Cartwright","doi":"10.3833/PDR.V2014I5.2027","DOIUrl":"https://doi.org/10.3833/PDR.V2014I5.2027","url":null,"abstract":"In a deal aimed at creating scale, France’s BioAlliance Pharma and Denmark’s Topotarget have agreed to combine their orphan oncology assets via a merger agreement. BioAlliance will be the continuing company and its shareholders will own approximately two-thirds of the combined entity. Topotarget’s sole asset is the pan-histone deacetylase (HDAC) inhibitor belinostat, which is awaiting a regulatory decision from the US FDA regarding its approval for the treatment of relapsed or refractory peripheral T-cell lymphoma. Belinostat will complement BioAlliance’s late-stage pipeline, which is led by Phase III Livatag® (doxorubicin Transdrug™) for advanced hepatocellular carcinoma.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2014-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85833388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vectura Ventures into Nebuliser Market with Activaero Purchase Vectura Ventures收购Activaero进入雾化器市场
Pharmadeals Review Pub Date : 2014-03-25 DOI: 10.3833/PDR.V2014I3.2016
Heather Cartwright
{"title":"Vectura Ventures into Nebuliser Market with Activaero Purchase","authors":"Heather Cartwright","doi":"10.3833/PDR.V2014I3.2016","DOIUrl":"https://doi.org/10.3833/PDR.V2014I3.2016","url":null,"abstract":"Furthering it ambition of becoming a speciality pharmaceutical company focused on respiratory diseases, UK-based pulmonary drug delivery company Vectura is to acquire Activaero in a deal worth up to €136 M (US$189 M). With the acquisition, Vectura will extend its technology offering with Activaero’s smart nebuliser-based technology Favorite® (flow and volume regulated inhalation technology). The deal will also strengthen and broaden the therapeutic focus of Vectura’s product pipeline. Activaero’s lead asset is Favolir® (nebulised budesonide by Akita® Jet), an aerosol therapy for patients with severe asthma who are dependent upon oral corticosteroids.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"76 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2014-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90063105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Regeneron Looks to Avalanche’s Ocular BioFactory™ for Potential Eylea® Successor Regeneron期待Avalanche的Ocular BioFactory™作为潜在的Eylea®继任者
Pharmadeals Review Pub Date : 2014-03-06 DOI: 10.3833/PDR.V2014I6.2036
Heather Cartwright
{"title":"Regeneron Looks to Avalanche’s Ocular BioFactory™ for Potential Eylea® Successor","authors":"Heather Cartwright","doi":"10.3833/PDR.V2014I6.2036","DOIUrl":"https://doi.org/10.3833/PDR.V2014I6.2036","url":null,"abstract":"In order to strengthen its ophthalmology pipeline and defend its Eylea® (aflibercept) franchise in the long term, Regeneron Pharmaceuticals has partnered with Avalanche Biotechnologies to develop and commercialise next-generation gene therapies for ophthalmologic diseases using Avalanche’s adeno-associated virus (AAV)-based Ocular BioFactory™ platform. The collaboration covers up to eight different targets and provides Regeneron with a time-limited right of first negotiation for certain rights to Avalanche’s lead asset AVA-101, which is in Phase IIa development for wet age-related macular degeneration.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"81 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2014-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86214896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Par Pharmaceutical Targets US Injectables Market with JHP Pharmaceuticals Purchase Par制药收购JHP制药，瞄准美国注射市场
Pharmadeals Review Pub Date : 2014-02-15 DOI: 10.3833/PDR.V2014I2.2009
Heather Cartwright
{"title":"Par Pharmaceutical Targets US Injectables Market with JHP Pharmaceuticals Purchase","authors":"Heather Cartwright","doi":"10.3833/PDR.V2014I2.2009","DOIUrl":"https://doi.org/10.3833/PDR.V2014I2.2009","url":null,"abstract":"TPG’s Par Pharmaceutical has agreed to acquire JHP Pharmaceuticals for US$490 M in cash in order to add branded and generic sterile injectables to its product offering. The deal comes only a year after Warburg Pincus acquired the company for US$195 M. With the acquisition, Par will gain access to JHP’s portfolio of 14 marketed speciality injectables and 34 generic pipeline candidates, 17 of which have been filed for US FDA approval. Sterile injectables comprise high-barrier-to-entry products that are difficult to manufacture and which have been the subject of numerous drug recalls and shortages in recent years.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"116 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2014-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73435497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Baxter Strengthens Haemophilia Franchise with Chatham Therapeutics Purchase as Biogen Enters Market 百特收购Chatham Therapeutics加强血友病特许经营，Biogen进入市场
Pharmadeals Review Pub Date : 2014-02-05 DOI: 10.3833/PDR.V2014I5.2023
Heather Cartwright
{"title":"Baxter Strengthens Haemophilia Franchise with Chatham Therapeutics Purchase as Biogen Enters Market","authors":"Heather Cartwright","doi":"10.3833/PDR.V2014I5.2023","DOIUrl":"https://doi.org/10.3833/PDR.V2014I5.2023","url":null,"abstract":"Baxter has agreed to acquire its partner Chatham Therapeutics in order to bolster its market-leading haemophilia franchise. News of the deal came less than a week after Baxter announced plans to spin off its biopharmaceuticals business into an independent company. With the acquisition, Baxter will gain broad access to Chatham’s gene therapy platform as well as full rights to BAX 355, a factor IX gene therapy for haemophilia B that is in Phase I/II development. Baxter faces competition in the haemophilia market from Biogen Idec, which received US FDA approval in March 2014 for Alprolix™, a long-acting recombinant factor IX for haemophilia B.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2014-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75296922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mylan Bolsters Global Injectables Business with Deal to Acquire Agila Specialities from Strides Arcolab 迈兰从Strides Arcolab收购Agila专业产品，促进全球注射剂业务
Pharmadeals Review Pub Date : 2013-12-03 DOI: 10.3833/pdr.v2013i3.1909
Heather Cartwright
{"title":"Mylan Bolsters Global Injectables Business with Deal to Acquire Agila Specialities from Strides Arcolab","authors":"Heather Cartwright","doi":"10.3833/pdr.v2013i3.1909","DOIUrl":"https://doi.org/10.3833/pdr.v2013i3.1909","url":null,"abstract":"Putting an end to speculation about the future of the division, India’s Strides Arcolab has agreed to divest its generic injectables unit Agila Specialities to Mylan for US$1.6 B in cash plus up to an additional US$250 M subject to the satisfaction of certain conditions by Strides. The deal, which values Agila at 6.3 times 2012 sales and 18.6 times EBITDA, will provide Mylan with critical mass in injectable drugs and an entry into high-growth emerging markets such as Brazil.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75649131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信